Schwartz R B, Holman B L, Polak J F, Garada B M, Schwartz M S, Folkerth R, Carvalho P A, Loeffler J S, Shrieve D C, Black P M, Alexander E
Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
J Neurosurg. 1998 Jul;89(1):60-8. doi: 10.3171/jns.1998.89.1.0060.
The study was conducted to determine the association between dual-isotope single-photon emission computerized tomography (SPECT) scanning and histopathological findings of tumor recurrence and survival in patients treated with high-dose radiotherapy for glioblastoma multiforme.
Studies in which SPECT with 201Tl and 99mTc-hexamethypropyleneamine oxime (HMPAO) were used were performed 1 day before reoperation in 47 patients with glioblastoma multiforme who had previously been treated by surgery and high-dose radiotherapy. Maximum uptake of 201Tl in the lesion was expressed as a ratio to that in the contralateral scalp, and uptake of 99mTc-HMPAO was expressed as a ratio to that in the cerebellar cortex. Patients were stratified into groups based on the maximum radioisotope uptake values in their tumor beds. The significance of differences in patient gender, histological characteristics of tissue at reoperation, and SPECT uptake group with respect to 1-year survival was elucidated by using the chi-square statistic. Comparisons of patient ages and time to tumor recurrence as functions of 1-year survival were made using the t-test. Survival data at 1 year were presented according to the Kaplan-Meier method, and the significance of potential differences was evaluated using the log-rank method. The effects of different variables (tumor type, time to recurrence, and SPECT grouping) on long-term survival were evaluated using Cox proportional models that controlled for age and gender. All patients in Group I (201Tl ratio < 2 and 99mTc-HMPAO ratio < 0.5) showed radiation changes in their biopsy specimens: they had an 83.3% 1-year survival rate. Group II patients (201Tl ratio < 2 and 99mTc-HMPAO ratio of > or = 0.5 or 201Tl ratio between 2 and 3.5 regardless of 99mTc-HMPAO ratio) had predominantly infiltrating tumor (66.6%); they had a 29.2% 1-year survival rate. Almost all of the patients in Group III (201Tl ratio > 3.5 and 99mTc-HMPAO ratio > or = 0.5) had solid tumor (88.2%) and they had a 6.7% 1-year survival rate. Histological data were associated with 1-year survival (p < 0.01): however, SPECT grouping was more closely associated with 1-year survival (p < 0.001) and was the only variable significantly associated with long-term survival (p < 0.005).
Dual-isotope SPECT data correlate with histopathological findings made at reoperation and with survival in patients with malignant gliomas after surgical and high-dose radiation therapy.
本研究旨在确定双同位素单光子发射计算机断层扫描(SPECT)与多形性胶质母细胞瘤大剂量放疗患者肿瘤复发的组织病理学结果及生存率之间的关联。
对47例先前接受过手术和大剂量放疗的多形性胶质母细胞瘤患者在再次手术前1天进行了使用201Tl和99mTc-六甲基丙烯胺肟(HMPAO)的SPECT研究。病变中201Tl的最大摄取量表示为与对侧头皮摄取量的比值,99mTc-HMPAO的摄取量表示为与小脑皮质摄取量的比值。根据肿瘤床中放射性同位素的最大摄取值将患者分层分组。使用卡方统计量阐明患者性别、再次手术时组织的组织学特征以及SPECT摄取组在1年生存率方面差异的显著性。使用t检验比较患者年龄和肿瘤复发时间作为1年生存率的函数。1年时的生存数据根据Kaplan-Meier方法呈现,并使用对数秩检验评估潜在差异的显著性。使用控制年龄和性别的Cox比例模型评估不同变量(肿瘤类型、复发时间和SPECT分组)对长期生存的影响。I组所有患者(201Tl比值<2且99mTc-HMPAO比值<0.5)活检标本显示有放射性改变:他们的1年生存率为83.3%。II组患者(201Tl比值<2且99mTc-HMPAO比值≥0.5或201Tl比值在2至3.5之间,无论99mTc-HMPAO比值如何)主要为浸润性肿瘤(66.6%);他们的1年生存率为29.2%。III组几乎所有患者(201Tl比值>3.5且99mTc-HMPAO比值≥0.5)有实体瘤(88.2%),他们的1年生存率为6.7%。组织学数据与1年生存率相关(p<0.01);然而,SPECT分组与1年生存率的相关性更强(p<0.001),并且是与长期生存显著相关的唯一变量(p<0.005)。
双同位素SPECT数据与再次手术时的组织病理学结果以及恶性胶质瘤患者手术和大剂量放疗后的生存率相关。